UBS Group
TVTX icon

UBS Group’s Travere Therapeutics TVTX Stock Holding History

UBS Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-67,500
Closed -$607K – 10030
2023
Q4 		$607K Sell
67,500
-71,900
-52% -$524K ﹤0.01% 4941
2023
Q3 		$1.25M Buy
139,400
+46,100
+49% +$650K ﹤0.01% 3883
2023
Q2 		$1.43M Buy
+93,300
New +$1.7M ﹤0.01% 3873
2016
Q3 		– Sell
-180,000
Closed -$3.21M – 7945
2016
Q2 		$3.21M Buy
+180,000
New +$2.91M ﹤0.01% 2376
2015
Q1 		– Sell
-500
Closed -$6K – 9387
2014
Q4 		$6K Buy
+500
New +$5.17K ﹤0.01% 8856

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's TVTX Position: Q2 2026 in Review

UBS Group reduced its Travere Therapeutics (TVTX) stake by 45% in Q2 2026, selling an estimated $17M and leaving 473,456 shares worth $26.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

UBS Group first reported a position in TVTX in Q2 2015 and has held it in 44 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • UBS Group held 473,456 shares of Travere Therapeutics worth $26.9M as of Q2 2026.
  • UBS Group sold 383,301 Travere Therapeutics shares in Q2 2026, an estimated $17M.
  • Travere Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2379 holding.
  • UBS Group first reported a position in Travere Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.